Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.34 |
| ▸ | APAF1 | O14727 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510389 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2HCAR3HTR3AALDH1A1MEN1 | |
| SCHEMBL23228197 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2HCAR3HTR3AALDH1A1MEN1 | |
| SCHEMBL18521164 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2HCAR3HTR3AALDH1A1MEN1 | |
| SCHEMBL20224934 | 0.79 | GDA (0.38) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL18521157 | 0.72 | CDK2 (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL15723760 | 0.71 | MEN1 (0.41) | SMN1; SMN2HCAR3ALDH1A1MEN1KMT2A | |
| SCHEMBL18520821 | 0.71 | SMN1; SMN2 (0.40) | SMN1; SMN2HCAR3HTR3AALDH1A1MEN1 | |
| SCHEMBL23619480 | 0.71 | PNP (0.41) | SMN1; SMN2MEN1KMT2AADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL28337380 | 0.70 | MEN1 (0.40) | SMN1; SMN2HCAR3ALDH1A1MEN1KMT2A | |
| SCHEMBL10001264 | 0.69 | MEN1 (0.45) | SMN1; SMN2ALDH1A1MEN1KMT2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | SMN1; SMN2 1815/4885HCAR3 1806/4885HTR3A 3981/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | SMN1; SMN2 1815/4885HCAR3 1806/4885HTR3A 3981/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | SMN1; SMN2 1484/4885HCAR3 2797/4885HTR3A 4187/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | SMN1; SMN2 1484/4885HCAR3 2797/4885HTR3A 4187/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | SMN1; SMN2 1484/4885HCAR3 2797/4885HTR3A 4187/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | SMN1; SMN2 1815/4885HCAR3 1806/4885HTR3A 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.